Thursday Tailwinds #8: Sep 24, 2026
ResMed benefits as Eli Lilly-funded sleep-apnoea diagnoses expand PAP demand, while NOV’s geothermal cutters and Po Valley’s unhedged…
NYSE
NOV
1 story
$6.7B Market cap · 2026-10-12
ResMed benefits as Eli Lilly-funded sleep-apnoea diagnoses expand PAP demand, while NOV’s geothermal cutters and Po Valley’s unhedged…
Companies the stories above are also about, besides NOV.